The effect of recombinant human growth hormone therapy on left-ventricular chamber size and function in children with

Ihsan Esen1, Ilker Cetin, Fatma Demirel

  • 1Department of Pediatric Endocrinology, Ankara Child's Health and Hematology Oncology Training Hospital, Irfan Bastug Cad. Kurtdereli Sok. No: 10, 06110, Altindag, Ankara, Turkey, esen_ihsan@yahoo.com.

Pediatric Cardiology
|June 14, 2013
PubMed

Insights

Recombinant human growth hormone (rhGH) therapy increases heart muscle mass in children with growth hormone deficiency (GHD). This cardiac remodeling occurs without altering heart function or geometry.

Area of Science:

  • Pediatric Endocrinology
  • Cardiology
  • Medical Imaging

Background:

  • Idiopathic isolated growth hormone deficiency (GHD) can affect cardiac structure.
  • Recombinant human growth hormone (rhGH) is a standard treatment for GHD.

Purpose of the Study:

  • To evaluate the impact of rhGH therapy on left-ventricular (LV) size and function in children with GHD.
  • To assess cardiac remodeling using echocardiography and tissue Doppler imaging (TDI).

Main Methods:

  • Thirty children with GHD received rhGH therapy for 12 months.
  • Conventional echocardiography and TDI were used to assess LV structure and function at baseline and follow-up intervals (3, 6, 12 months).

Main Results:

  • Significant increases in LV mass (LVM) and relative wall thickness (RWT) were observed after 3 months of rhGH treatment.
  • LVM normalized and showed a steady increase up to 12 months, without exceeding normal limits.
  • No significant changes in LV functional parameters or interventricular septum were detected.

Conclusions:

  • rhGH therapy induces concentric myocardial remodeling, increasing LV mass without adverse effects on cardiac geometry or function.
  • The observed increase in myocardial mass is adaptive remodeling rather than pathological hypertrophy.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...